Financial Data and Key Metrics Changes - Total revenue in Q2 2024 grew to $231 million, supporting full-year growth expectations of 13% to 22% [6][35] - Royalty revenue reached $125 million, an increase of 12% year-over-year, marking the 16th consecutive quarter of double-digit year-on-year royalty growth [6][35] - Adjusted EBITDA grew by 19% to $137 million, with non-GAAP diluted earnings per share increasing by 23% to $0.91 [6][37] Business Line Data and Key Metrics Changes - The ENHANZE IP portfolio was strengthened with a new patent granted in Europe, extending coverage to March 6, 2029 [7][8] - The approval of OCREVUS subcutaneous and VYVGART Hytrulo expanded ENHANZE's reach into neurology and autoimmune diseases [9][10] - Sales of DARZALEX in Q2 were $2.9 billion, a 21.3% increase year-over-year, driven by share gains across therapy lines [15][16] Market Data and Key Metrics Changes - OCREVUS subcutaneous has a PDUFA action date of September 13, 2024, with the brand maintaining a 26% global patient share [25][26] - Phesgo sales increased by 60% to almost CHF800 million in the first half of 2024, with Roche expecting global conversion to reach 50% by 2026 [17] - Nivolumab IV sales grew 16% to $2.4 billion in Q2, with expectations for significant conversion to subcutaneous formulations [27] Company Strategy and Development Direction - The company aims to achieve $1 billion in royalty revenue by 2027, driven by strong performance from Wave 2 products and new royalty streams from Wave 3 products [14] - The focus remains on expanding ENHANZE technology into new treatment areas, with ongoing discussions for new partnerships [41][50] - The company is actively seeking M&A opportunities, particularly in drug delivery and licensing models that align with its high-margin business profile [74] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in achieving financial targets, citing a strong pipeline of launches and growing awareness of subcutaneous technology [39] - The company anticipates continued growth in royalty revenue, particularly in the second half of the year, following the reinstatement of full royalty rates [38][70] - Management noted that external factors like election uncertainty have not impacted partnership discussions [54] Other Important Information - The company completed a $250 million ASR, bringing total shareholder returns via share repurchases to $1.3 billion over five years [34] - Cash and marketable securities increased to $529 million as of June 30, 2024, reflecting strong operational cash generation [35] Q&A Session Summary Question: Overview of new partnership activities - Management is confident in securing additional deals, primarily focused on ENHANZE technology, with a mix of established and early-stage products [41] Question: Drivers of higher-than-expected API sales - API sales were higher due to partner demand shifts, with expectations for flat sales in Q3 [42][43] Question: Potential partnerships in the myostatin pathway - The company is interested in targeting obesity and muscle loss areas and is actively reaching out to relevant companies [46] Question: Updates on undisclosed Roche and Chugai products - Details on these products remain confidential, and no near-term disclosure plans have been indicated by partners [49] Question: Impact of PALOMA 3 results on partnership discussions - The PALOMA 3 results have generated interest, particularly in areas like nucleic acids and mRNA, but further data is needed [51] Question: Expectations for new ENHANZE deals - Management remains optimistic about signing new deals this year, with ongoing discussions with around 10 companies [70][71]

For the quarter ended June 2024, Halozyme Therapeutics (HALO) reported revenue of $231.35 million, up 4.7% over the same period last year. EPS came in at $0.91, compared to $0.74 in the year-ago quarter. The reported revenue compares to the Zacks Consensus Estimate of $210.92 million, representing a surprise of +9.69%. The company delivered an EPS surprise of +16.67%, with the consensus EPS estimate being $0.78. While investors scrutinize revenue and earnings changes year-over-year and how they compare with ...

Halozyme Therapeutics (HALO) came out with quarterly earnings of $0.91 per share, beating the Zacks Consensus Estimate of $0.78 per share. This compares to earnings of $0.74 per share a year ago. These figures are adjusted for non-recurring items. This quarterly report represents an earnings surprise of 16.67%. A quarter ago, it was expected that this biopharmaceutical company would post earnings of $0.69 per share when it actually produced earnings of $0.79, delivering a surprise of 14.49%. Over the last f ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 _______________________________________ FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-32335 HALOZYME THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) ...

Exhibit 99.1 HALOZYME REPORTS SECOND QUARTER 2024 FINANCIAL AND OPERATING RESULTS Total Revenue of $231 million; Net Income of $93 million; Adjusted EBITDA of $137 million; GAAP Diluted EPS of $0.72 and Non-GAAP Diluted EPS of $0.91 1 Royalty Revenue Increased 12% YOY to $125 million ® ® Partner Approvals for Ocrevus SC in Europe and the UK and VYVGART Hytrulo for CIDP in the U.S. Maintain Recently Increased 2024 Financial Guidance: Total Revenue of $935 - $1,015 million, Representing YOY Growth of 13% - 22 ...

The popular research service can help you become a smarter, more self-assured investor, giving you access to daily updates of the Zacks Rank and Zacks Industry Rank, the Zacks #1 Rank List, Equity Research reports, and Premium stock screens. The Zacks Style Scores is a unique set of guidelines that rates stocks based on three popular investing types, and were developed as complementary indicators for the Zacks Rank. This combination helps investors choose securities with the highest chances of beating the m ...

SAN DIEGO, July 23, 2024 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) ("Halozyme") today announced it will release its second quarter 2024 financial and operating results on Tuesday, August 6, 2024, following the close of trading. Halozyme will host a conference call on Tuesday, August 6, 2024 at 1:30 p.m. PT/4:30 p.m. ET to discuss the results. The conference call may be accessed live with pre-registration via this link: https://registrations.events/direct/Q4I8719057. A live webcast and repla ...

But the risks certainly match the rewards. One of the main characteristics of biotech companies is that they depend heavily on drug approvals from the Food and Drug Administration (FDA) and patent protection upon treatment development, which makes it difficult to predict the future outlook of individual stocks. Biotech companies also need heavy investment into research and development (R&D) in order to remain competitive, which requires high cash reserves and aggressive borrowing. Moderna (MRNA) Using its M ...

FX Empire Logo Español Português Important DisclaimersThe content provided on the website includes general news and publications, our personal analysis and opinions, and contents provided by third parties, which are intended for educational and research purposes only. It does not constitute, and should not be read as, any recommendation or advice to take any action whatsoever, including to make any investment or buy any product. When making any financial decision, you should perform your own due diligence c ...

Growth investors focus on stocks that are seeing above-average financial growth, as this feature helps these securities garner the market's attention and deliver solid returns. But finding a growth stock that can live up to its true potential can be a tough task. In addition to volatility, these stocks carry above-average risk by their very nature. Also, one could end up losing from a stock whose growth story is actually over or nearing its end. However, the Zacks Growth Style Score (part of the Zacks Style ...